IQVIA (IQV) Q3 2026 Earnings Call: Guidance and Outlook
Management raised its full year 2026 formal guidance for revenue, adjusted EBITDA, and adjusted diluted EPS.
About IQVIA. IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific.
No specific formal quarterly guidance figures were provided for the fourth quarter.
Annual guidance
Revenue
$17,350 billion to $17,500 billion, representing year-over-year growth of 6.4% to 7.3%.
Adjusted EBITDA
$4.025 billion to $4.055 billion, growing 6.3% to 7% year-over-year.
Adjusted Diluted EPS
$12.90 to $13, up 8.2% to 9.1% versus prior year.
Outlook
Biotech funding
The biotech funding environment continues to be very strong, reaching $90 billion year-to-date and up more than 85% year-over-year.
Commercial demand
The demand outlook remains favorable with new drug launches up more than 40% year-to-date and decision timelines continuing to shorten.
Clinical demand
Clinical trial starts year-to-date are up high single digits and RFP flow continued to grow at a healthy rate at high single digits.
Below the line items
For the fourth quarter, net interest expense is expected to be around $210 million, depreciation and amortization just over $160 million, and weighted average diluted share count approximately 169 million shares.
Dombey's summary of the IQVIA Q3 2026 earnings call held Oct 27, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
